Yuzhou Zhang1, Nicole C Meyer1, Fernando C Fervenza2, Winnie Lau3, Adam Keenan1, Gabriel Cara-Fuentes4, Dingwu Shao1, Aalia Akber5, Veronique Fremeaux-Bacchi6, Sanjeev Sethi7, Carla M Nester8, Richard J H Smith9. 1. Molecular Otolaryngology and Renal Research Laboratories, Carver College of Medicine, University of Iowa, Iowa City, IA. 2. Department of Internal Medicine, Mayo Clinic, Rochester, MN. 3. Internal Medicine, Nephrology, Indian River Medical Center, Vero Beach, FL. 4. Department of Pediatrics, University of Florida, Gainesville, FL. 5. Department of Nephrology, Kaiser Permanente, Oakland, CA. 6. Department of Immunology, Hospital European Georges Pompidou, AP-HP, Paris, France. 7. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN. 8. Molecular Otolaryngology and Renal Research Laboratories, Carver College of Medicine, University of Iowa, Iowa City, IA; Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA. 9. Molecular Otolaryngology and Renal Research Laboratories, Carver College of Medicine, University of Iowa, Iowa City, IA; Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA. Electronic address: richard-smith@uiowa.edu.
Abstract
BACKGROUND: C3 glomerulopathy (C3G) defines a group of rare complement-mediated kidney diseases with a shared underlying pathophysiology: dysregulation of complement in the fluid phase and glomerular microenvironment. Dysregulation can be driven by autoantibodies to C3 and C5 convertases. STUDY DESIGN: Case series. SETTING & PARTICIPANTS: 168 patients with C3G (dense deposit disease, 68; C3 glumerulonephritis, 100) selected from our C3G biobank. OUTCOMES: Patient-purified immunoglobulin Gs were tested for C4 nephritic factors (C4NeFs). These autoantibodies recognize C4b2a, the C3 convertase of the classical pathway of complement. MEASUREMENTS: C4NeFs were detected using a modified hemolytic assay. RESULTS: C4NeFs were identified in 5 patients, 4 of whom had C3 glomerulonephritis. C4NeFs were associated with dysregulation of C3 and C5 convertases, and they appear to stabilize these convertases in a dose-dependent manner. C4NeFs also appear to protect C4b2a from decay mediated by soluble CR1 and C4 binding protein. The stabilizing activity of the autoantibodies was further demonstrated by using heat treatment to inactivate complement. C4NeFs were not detected in 150 patients with another complement-mediated kidney disease, atypical hemolytic uremic syndrome. They were also absent in 300 apparently healthy controls. LIMITATIONS: In addition to C4NeFs, 2 patients had positive findings for other autoantibodies: one patient also had autoantibodies to factor H; the other patient also had autoantibodies to C3bBb (C3NeFs). CONCLUSIONS: The finding of C4NeFs in a small percentage of patients with C3G highlights the challenge in identifying autoantibodies that drive complement dysregulation and underscores the complexity of the autoantibody repertoire that can be identified in these patients.
BACKGROUND:C3 glomerulopathy (C3G) defines a group of rare complement-mediated kidney diseases with a shared underlying pathophysiology: dysregulation of complement in the fluid phase and glomerular microenvironment. Dysregulation can be driven by autoantibodies to C3 and C5 convertases. STUDY DESIGN: Case series. SETTING & PARTICIPANTS: 168 patients with C3G (dense deposit disease, 68; C3 glumerulonephritis, 100) selected from our C3G biobank. OUTCOMES: Patient-purified immunoglobulin Gs were tested for C4 nephritic factors (C4NeFs). These autoantibodies recognize C4b2a, the C3 convertase of the classical pathway of complement. MEASUREMENTS: C4NeFs were detected using a modified hemolytic assay. RESULTS: C4NeFs were identified in 5 patients, 4 of whom had C3 glomerulonephritis. C4NeFs were associated with dysregulation of C3 and C5 convertases, and they appear to stabilize these convertases in a dose-dependent manner. C4NeFs also appear to protect C4b2a from decay mediated by soluble CR1 and C4 binding protein. The stabilizing activity of the autoantibodies was further demonstrated by using heat treatment to inactivate complement. C4NeFs were not detected in 150 patients with another complement-mediated kidney disease, atypical hemolytic uremic syndrome. They were also absent in 300 apparently healthy controls. LIMITATIONS: In addition to C4NeFs, 2 patients had positive findings for other autoantibodies: one patient also had autoantibodies to factor H; the other patient also had autoantibodies to C3bBb (C3NeFs). CONCLUSIONS: The finding of C4NeFs in a small percentage of patients with C3G highlights the challenge in identifying autoantibodies that drive complement dysregulation and underscores the complexity of the autoantibody repertoire that can be identified in these patients.
Authors: Nicholas R Medjeral-Thomas; Michelle M O'Shaughnessy; John A O'Regan; Carol Traynor; Michael Flanagan; Limy Wong; Chia Wei Teoh; Atif Awan; Mary Waldron; Tom Cairns; Patrick O'Kelly; Anthony M Dorman; Matthew C Pickering; Peter J Conlon; H Terence Cook Journal: Clin J Am Soc Nephrol Date: 2013-10-31 Impact factor: 8.237
Authors: Maria Asuncion Abrera-Abeleda; Carla Nishimura; Kathy Frees; Michael Jones; Tara Maga; Louis M Katz; Yuzhou Zhang; Richard J H Smith Journal: J Am Soc Nephrol Date: 2011-07-22 Impact factor: 10.121
Authors: Peter F Zipfel; Christine Skerka; Qian Chen; Thorsten Wiech; Tim Goodship; Sally Johnson; Veronique Fremeaux-Bacchi; Clara Nester; Santiago Rodríguez de Córdoba; Marina Noris; Matthew Pickering; Richard Smith Journal: Mol Immunol Date: 2015-04-28 Impact factor: 4.407
Authors: Yuzhou Zhang; Nicole C Meyer; Kai Wang; Carla Nishimura; Kathy Frees; Michael Jones; Louis M Katz; Sanjeev Sethi; Richard J H Smith Journal: Clin J Am Soc Nephrol Date: 2012-01-05 Impact factor: 8.237
Authors: Fengxiao Bu; Nicolo Ghiringhelli Borsa; Michael B Jones; Erika Takanami; Carla Nishimura; Jill J Hauer; Hela Azaiez; Elizabeth A Black-Ziegelbein; Nicole C Meyer; Diana L Kolbe; Yingyue Li; Kathy Frees; Michael J Schnieders; Christie Thomas; Carla Nester; Richard J H Smith Journal: J Am Soc Nephrol Date: 2015-08-17 Impact factor: 10.121
Authors: Daniel P Gale; Elena Goicoechea de Jorge; H Terence Cook; Rubén Martinez-Barricarte; Andreas Hadjisavvas; Adam G McLean; Charles D Pusey; Alkis Pierides; Kyriacos Kyriacou; Yiannis Athanasiou; Konstantinos Voskarides; Constantinos Deltas; Andrew Palmer; Véronique Frémeaux-Bacchi; Santiago Rodriguez de Cordoba; Patrick H Maxwell; Matthew C Pickering Journal: Lancet Date: 2010-08-25 Impact factor: 79.321
Authors: Agustín Tortajada; Hugo Yébenes; Cynthia Abarrategui-Garrido; Jaouad Anter; Jesús M García-Fernández; Rubén Martínez-Barricarte; María Alba-Domínguez; Talat H Malik; Rafael Bedoya; Rocío Cabrera Pérez; Margarita López Trascasa; Matthew C Pickering; Claire L Harris; Pilar Sánchez-Corral; Oscar Llorca; Santiago Rodríguez de Córdoba Journal: J Clin Invest Date: 2013-06 Impact factor: 14.808
Authors: Elizabeth C Miller; Nicole M Chase; Peter Densen; Mary K Hintermeyer; James T Casper; John P Atkinson Journal: Clin Immunol Date: 2012-09-28 Impact factor: 3.969
Authors: Sanjeev Sethi; Fernando C Fervenza; Yuzhou Zhang; Ladan Zand; Nicole C Meyer; Nicolò Borsa; Samih H Nasr; Richard J H Smith Journal: Kidney Int Date: 2012-12-12 Impact factor: 10.612
Authors: Richard J H Smith; Gerald B Appel; Anna M Blom; H Terence Cook; Vivette D D'Agati; Fadi Fakhouri; Véronique Fremeaux-Bacchi; Mihály Józsi; David Kavanagh; John D Lambris; Marina Noris; Matthew C Pickering; Giuseppe Remuzzi; Santiago Rodriguez de Córdoba; Sanjeev Sethi; Johan Van der Vlag; Peter F Zipfel; Carla M Nester Journal: Nat Rev Nephrol Date: 2019-03 Impact factor: 28.314
Authors: Edwin K S Wong; Kevin J Marchbank; Hannah Lomax-Browne; Isabel Y Pappworth; Harriet Denton; Katie Cooke; Sophie Ward; Amy-Claire McLoughlin; Grant Richardson; Valerie Wilson; Claire L Harris; B Paul Morgan; Svetlana Hakobyan; Paul McAlinden; Daniel P Gale; Heather Maxwell; Martin Christian; Roger Malcomson; Timothy H J Goodship; Stephen D Marks; Matthew C Pickering; David Kavanagh; H Terence Cook; Sally A Johnson Journal: Clin J Am Soc Nephrol Date: 2021-09-22 Impact factor: 8.237
Authors: Aishwarya Ravindran; Fernando C Fervenza; Richard J H Smith; An S De Vriese; Sanjeev Sethi Journal: Mayo Clin Proc Date: 2018-08 Impact factor: 7.616
Authors: Keri A Drake; Natalie Ellington; Jyothsna Gattineni; Jose R Torrealba; Allen R Hendricks Journal: Pediatr Nephrol Date: 2019-10-30 Impact factor: 3.714